The KEX02 live bacteria capsule combined with PD-1 inhibitor for the treatment of non-small cell lung cancer is in Phase I clinical trials.
October 29, 2025
Source: drugdu
77
an investor asked on the investor interaction platform: Regarding the innovative intestinal microecology drugs of the subsidiary Juntuo Biotechnology.What is the progress of the pipeline? What is the progress of the trial of combining PD-1 inhibitors for the treatment of non-small cell lung cancer?
Ketuo BioOn October 24, 2019, the company (300858.SZ) announced on its investor engagement platform that it and Shenzhen Weizhijun Biotechnology Co., Ltd. are steadily advancing clinical research on their pipeline drug, KEX02 Live Bacteria Capsules, in combination with a PD-1 inhibitor for the treatment of non-small cell lung cancer. The project is currently in Phase I clinical trials. The company will disclose information promptly based on progress.
Source：https://finance.eastmoney.com/a/202510243543555259.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
